AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37536752 — intervention group
Group type: EXPERIMENTAL
Intervention: 2020 (Pandemic)
Number of subjects: 430
Study 37536752 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression status
Number of subjects: 430
Study 37536752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care unit
Number of subjects: 430
Study 37536752 — intervention group
Group type: EXPERIMENTAL
Intervention: Visits from relatives
Number of subjects: 430
Study 37536753 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-assisted suicide
Number of subjects: 331
Study 37536753 — intervention group
Group type: EXPERIMENTAL
Intervention: Euthanasia
Number of subjects: 331
Study 37536753 — intervention group
Group type: COMPARATOR
Intervention: Cultural factors
Number of subjects: 331
Study 37536753 — intervention group
Group type: COMPARATOR
Intervention: Belief in God
Number of subjects: 331
Study 37536931 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcification present
Number of subjects: 39
Study 37536931 — intervention group
Group type: COMPARATOR
Intervention: No calcification
Number of subjects: 39
Study 37536931 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrocalcification
Number of subjects: 39
Study 37536931 — intervention group
Group type: EXPERIMENTAL
Intervention: Spotty calcification
Number of subjects: 39
Study 37536936 — intervention group
Group type: EXPERIMENTAL
Intervention: TLPLDC (n=103)
Number of subjects: 187
Study 37536936 — intervention group
Group type: EXPERIMENTAL
Intervention: TLPLDC+G (n=56)
Number of subjects: 187
Study 37536936 — intervention group
Group type: EXPERIMENTAL
Intervention: TLPO (n=43)
Number of subjects: 187
Study 37536936 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 187
Study 37536941 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks for a total of 17 doses) and ipilimumab (1 mg/kg every 6 weeks for a total of 6 doses) starting 2 weeks prior to radiotherapy
Number of subjects: 24
Study 37536941 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab
Number of subjects: 24
Study 37536965 — intervention group
Group type: EXPERIMENTAL
Intervention: PBP e-learning (group 2)
Number of subjects: 120
Study 37536965 — intervention group
Group type: COMPARATOR
Intervention: HSE course (group 1)
Number of subjects: 120
Study 37536965 — intervention group
Group type: COMPARATOR
Intervention: Self-directed e-learning (S) (group 3)
Number of subjects: 120
Study 37537219 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg daily)
Number of subjects: 47
Study 37537324 — intervention group
Group type: EXPERIMENTAL
Intervention: Vie Scope
Number of subjects: 58
Study 37537324 — intervention group
Group type: COMPARATOR
Intervention: Macintosh videolaryngoscopy (C-MAC®)
Number of subjects: 58
Study 37537324 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 37537541 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved site irradiation (ISI)
Number of subjects: 414
Study 37537541 — intervention group
Group type: COMPARATOR
Intervention: Elective region irradiation (ERI)
Number of subjects: 414
Study 37537548 — intervention group
Group type: EXPERIMENTAL
Intervention: Two distinct approaches to involving parents in adolescent obesity treatment
Number of subjects: 210
Study 37537563 — intervention group
Group type: EXPERIMENTAL
Intervention: Day surgery (DS) for varicose veins with SVT below knee
Number of subjects: 593
Study 37537563 — intervention group
Group type: COMPARATOR
Intervention: Day surgery (DS) for varicose veins without SVT
Number of subjects: 593
Study 37537563 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SVT and VV only)
Number of subjects: 593
Study 37537576 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipidomic Risk (LR) score based on 15 lipid species identified by Random Survival Forest (RSF)
Number of subjects: 462
Study 37537576 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher LR Score values
Number of subjects: 462
Study 37537576 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined clinical variables and selected lipidic isomers
Number of subjects: 462
Study 37537580 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 1867
Study 37537580 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular weight heparin (LMWH) alone
Number of subjects: 1867
Study 37537580 — intervention group
Group type: COMPARATOR
Intervention: LMWH and aspirin
Number of subjects: 1867
Study 37537580 — intervention group
Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 1867
Study 37537847 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for the upper limb (arm ergometer exercises)
Number of subjects: 48
Study 37537847 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for the lower limb (cycling)
Number of subjects: 48
Study 37537847 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as group A)
Number of subjects: 48
Study 37537894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (CR) intervention via telerehabilitation (TR) method for 12 weeks
Number of subjects: 68
Study 37537894 — intervention group
Group type: COMPARATOR
Intervention: Cognitive rehabilitation (CR) intervention via face-to-face method for 12 weeks
Number of subjects: 68
Study 37537928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast
Number of subjects: 255
Study 37537928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 37538173 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib
Number of subjects: 0
Study 37538173 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib (QD dosing)
Number of subjects: 0
Study 37538332 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor daylight PDT (30 min of 5-aminolevulinic acid (ALA) pre-incubation, followed by 2 h of indoor sunlight)
Number of subjects: 41
Study 37538332 — intervention group
Group type: COMPARATOR
Intervention: Lamp-based PDT (30 min of ALA pre-incubation, followed by 10 min of red light)
Number of subjects: 41
Study 37538505 — intervention group
Group type: EXPERIMENTAL
Intervention: octocog alfa
Number of subjects: 13
Study 37538505 — intervention group
Group type: EXPERIMENTAL
Intervention: rurioctocog alfa pegol
Number of subjects: 13
Study 37538505 — intervention group
Group type: EXPERIMENTAL
Intervention: efanesoctocog alfa
Number of subjects: 13
Study 37538539 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 125 μg subcutaneous pegylated IFNβ-1a
Number of subjects: 1172
Study 37538539 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1172
Study 37538951 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin monotherapy (5 mg/kg once followed by 1.67 mg/kg every 8 hours)
Number of subjects: 423
Study 37538951 — intervention group
Group type: COMPARATOR
Intervention: Colistin in combination with meropenem (1000 mg every 8 hours)
Number of subjects: 423
Study 37539061 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) for 28 days
Number of subjects: 399
Study 37539698 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-MY20
Number of subjects: 276
Study 37539698 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30
Number of subjects: 276
Study 37539981 — intervention group
Group type: EXPERIMENTAL
Intervention: Delandistrogene moxeparvovec (1.33 × 10^14 vg/kg)
Number of subjects: 20
Study 37539981 — intervention group
Group type: EXPERIMENTAL
Intervention: Delandistrogene moxeparvovec
Number of subjects: 20
Study 37540036 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) added to furosemide, eGFR-adjusted doses
Number of subjects: 230
Study 37540036 — intervention group
Group type: COMPARATOR
Intervention: Furosemide alone (control)
Number of subjects: 230
Study 37540060 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 530
Study 37540060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 37540159 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) combined with glucocorticoids (GCs) and MTX
Number of subjects: 40
Study 37540159 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab (TCZ) combined with glucocorticoids (GCs) and MTX
Number of subjects: 40
Study 37540206 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL200
Number of subjects: 86
Study 37540206 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL100
Number of subjects: 86
Study 37540289 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced miR-195
Number of subjects: 101
Study 37540289 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased miR-10b
Number of subjects: 101
Study 37540289 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased miR-145
Number of subjects: 101
Study 37540289 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased miR-21
Number of subjects: 101
Study 37540312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar anodal transcranial direct current stimulation (C-tDCS)
Number of subjects: 7
Study 37540312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebello-spinal cathodal transcranial direct current stimulation (CS-tDCS)
Number of subjects: 7
Study 37540323 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual volume (RV)
Number of subjects: 210
Study 37540323 — intervention group
Group type: EXPERIMENTAL
Intervention: Half of the maximum volume (MV)
Number of subjects: 210
Study 37540323 — intervention group
Group type: EXPERIMENTAL
Intervention: Unchanged volume (NV)
Number of subjects: 210
Study 37540323 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 210
Study 37540383 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy with 10% dextrose concentration (Group 2)
Number of subjects: 128
Study 37540383 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy with 20% dextrose concentration (Group 3)
Number of subjects: 128
Study 37540383 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy with 5% dextrose concentration (Group 1)
Number of subjects: 128
Study 37540383 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program (Group 4)
Number of subjects: 128
Study 37540556 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic therapy (bevacizumab ± irinotecan, cabozantinib)
Number of subjects: 350
Study 37540566 — intervention group
Group type: EXPERIMENTAL
Intervention: One or two infusions of third-generation CD19-directed CAR-Ts (2 × 10^8/m2)
Number of subjects: 24
Study 37540566 — intervention group
Group type: EXPERIMENTAL
Intervention: Effector-like CD8+CAR-Ts with a high polyfunctionality, high cytotoxic and cytokine production profile, and low dysfunctional signature
Number of subjects: 24
Study 37540566 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended ex vivo expansion time during CAR-T manufacturing
Number of subjects: 24
Study 37540593 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormones (TSH, T3, T4) and sex hormones (PRL, total testosterone) measured preoperatively and at 24 h postoperatively
Number of subjects: 49
Study 37540593 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU hours, mechanical ventilation, and Vasoactive-Inotropic Score (VIS)
Number of subjects: 49
Study 37540593 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU hours
Number of subjects: 49
Study 37540593 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative and delta testosterone levels
Number of subjects: 49
Study 37540593 — intervention group
Group type: EXPERIMENTAL
Intervention: Model for End-Stage Liver Disease (MELD) scores
Number of subjects: 49
Study 37540649 — intervention group
Group type: EXPERIMENTAL
Intervention: Index HIV self-testing (HIVST) with HIVST kits and instructions
Number of subjects: 484
Study 37540649 — intervention group
Group type: COMPARATOR
Intervention: Standard partner referral slip (PRS)
Number of subjects: 484
Study 37540692 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Hz tACS
Number of subjects: 0
Study 37540692 — intervention group
Group type: COMPARATOR
Intervention: tDCS
Number of subjects: 0
Study 37540692 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 37540921 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT plus TIL infusion (n = 78)
Number of subjects: 156
Study 37540921 — intervention group
Group type: COMPARATOR
Intervention: CCRT alone (n = 78)
Number of subjects: 156
Study 37541047 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck extension during palatoplasty
Number of subjects: 37
Study 37541263 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (randomised pathway)
Number of subjects: 221
Study 37541263 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment (randomised pathway)
Number of subjects: 221
Study 37541263 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (patient choice pathway)
Number of subjects: 221
Study 37541263 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment (patient choice pathway)
Number of subjects: 221
Study 37541273 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib (8 mg/day, with potential up-titration to 9 mg/day)
Number of subjects: 217
Study 37541600 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-Contingent Wage Supplement
Number of subjects: 119
Study 37541600 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Control
Number of subjects: 119
Study 37541626 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity (VA) assessment in ZSD patients
Number of subjects: 185
Study 37541626 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal visual acuity data
Number of subjects: 185
Study 37541626 — intervention group
Group type: EXPERIMENTAL
Intervention: Funduscopy findings
Number of subjects: 185
Study 37541626 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroretinography findings
Number of subjects: 185
Study 37541626 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT findings in milder patients
Number of subjects: 185
Study 37541626 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic measures for assessing retinal dystrophy
Number of subjects: 185
Study 37541683 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ropivacaine 0.2% 4-8 mL/hour
Number of subjects: 60
Study 37541683 — intervention group
Group type: COMPARATOR
Intervention: Single injection of ropivacaine 0.5%, 20 mL
Number of subjects: 60
Study 37541705 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible and immediate-release FDC abacavir (60 mg or 600 mg), dolutegravir (5 mg or 50 mg), and lamivudine (30 mg or 300 mg) tablets taken once per day.
Number of subjects: 57
Study 37541706 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic multilevel health system intervention including life-stage-based assessment, flexible clinic access, and rapid viral load feedback.
Number of subjects: 1549
Study 37541706 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 1549
Study 37541706 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic multilevel health system intervention.
Number of subjects: 1549
Study 37541743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazodalibep (DAZ)
Number of subjects: 78
Study 37541743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 78
Study 37541745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant 0.7 mg (DEX)
Number of subjects: 143
Study 37541748 — intervention group
Group type: EXPERIMENTAL
Intervention: EnSite Precision 3D mapping system
Number of subjects: 700
Study 37541750 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota profiling in stools and saliva, microbial metabolites quantification in stools, and Treg/Th17 balance characterisation in patients with AA syndrome.
Number of subjects: 30
Study 37541750 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (matched to patients with AA syndrome).
Number of subjects: 30
Study 37541829 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT+ intervention (6-session family-based health promotion program integrating mindfulness strategies)
Number of subjects: 95
Study 37541829 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) (1-session)
Number of subjects: 95
Study 37541921 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.36 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily for 30 months
Number of subjects: 241
Study 37541921 — intervention group
Group type: COMPARATOR
Intervention: None (Control)
Number of subjects: 241
Study 37541921 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise treadmill testing measuring METs
Number of subjects: 241
Study 37541921 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 241
Study 37541921 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual CAC progression
Number of subjects: 241
Study 37541951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (subanaesthetic doses, blood concentration of 0.2-0.3 μg ml)
Number of subjects: 14
Study 37541951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (subanaesthetic doses)
Number of subjects: 14
Study 37541984 — intervention group
Group type: EXPERIMENTAL
Intervention: mNGS (metagenomic next-generation sequencing) within 7 days
Number of subjects: 101
Study 37541984 — intervention group
Group type: COMPARATOR
Intervention: mNGS (metagenomic next-generation sequencing) after 7 days
Number of subjects: 101
Study 37541984 — intervention group
Group type: EXPERIMENTAL
Intervention: mNGS
Number of subjects: 101
Study 37541984 — intervention group
Group type: COMPARATOR
Intervention: Conventional tests
Number of subjects: 101
Study 37542140 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic rotator cuff tears
Number of subjects: 75
Study 37542140 — intervention group
Group type: EXPERIMENTAL
Intervention: All muscles and shoulder types
Number of subjects: 75
Study 37542140 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-kg increments in additional weights
Number of subjects: 75
Study 37542140 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator cuff pathologies
Number of subjects: 75
Study 37542143 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-exposed childhood cancer survivors with cardiomyopathy
Number of subjects: 104
Study 37542143 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline-exposed childhood cancer survivors without cardiomyopathy
Number of subjects: 104
Study 37542155 — intervention group
Group type: COMPARATOR
Intervention: Term Reference (TR) infants, 183 subjects, assessed at 2 years of age.
Number of subjects: 1452
Study 37542217 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtarsal approach (Group A)
Number of subjects: 24
Study 37542217 — intervention group
Group type: COMPARATOR
Intervention: Conventional transconjunctival approach (Group B)
Number of subjects: 24
Study 37542217 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-modification of the transconjunctival approach (Group C)
Number of subjects: 24
Study 37542222 — intervention group
Group type: EXPERIMENTAL
Intervention: GMB/GMB group (galcanezumab 120 mg)
Number of subjects: 96
Study 37542222 — intervention group
Group type: COMPARATOR
Intervention: PBO/GMB group (placebo followed by galcanezumab 240 mg loading dose and then two 120 mg doses)
Number of subjects: 96
Study 37542222 — intervention group
Group type: EXPERIMENTAL
Intervention: GMB/GMB group
Number of subjects: 96
Study 37542222 — intervention group
Group type: EXPERIMENTAL
Intervention: GMB/GMB group and PBO/GMB group
Number of subjects: 96
Study 37542234 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise snacking intervention (twice daily for 28 days, consisting of five muscle-strengthening exercises)
Number of subjects: 21
Study 37542331 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast Task training (5 sessions, 45 minutes each, delivered online, twice a week)
Number of subjects: 24
Study 37542335 — intervention group
Group type: EXPERIMENTAL
Intervention: NuroSleeve
Number of subjects: 0
Study 37542447 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Ti cages
Number of subjects: 50
Study 37542447 — intervention group
Group type: COMPARATOR
Intervention: PEEK cages
Number of subjects: 50
Study 37542470 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (LAN) treatment initiation
Number of subjects: 115
Study 37542470 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (LAN) treatment
Number of subjects: 115
Study 37542529 — intervention group
Group type: EXPERIMENTAL
Intervention: Males (95 injuries, 262 injury weeks)
Number of subjects: 462
Study 37542529 — intervention group
Group type: EXPERIMENTAL
Intervention: Females (350 injuries, 1206 injury weeks)
Number of subjects: 462
Study 37542529 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher age
Number of subjects: 462
Study 37542529 — intervention group
Group type: EXPERIMENTAL
Intervention: Present injury at baseline
Number of subjects: 462
Study 37542556 — intervention group
Group type: EXPERIMENTAL
Intervention: Aperture fixation with biodegradable interference screws
Number of subjects: 21
Study 37542556 — intervention group
Group type: COMPARATOR
Intervention: All-inside ACLR with suspensory cortical buttons
Number of subjects: 21
Study 37542674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-oral sulfate tablet (mini-OST)
Number of subjects: 83
Study 37542674 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral sulfate tablet (OST)
Number of subjects: 83
Study 37542918 — intervention group
Group type: EXPERIMENTAL
Intervention: Published rocuronium PK/PD models (Wierda, Szenohradszky, Cooper, Alvarez-Gomez, McCoy)
Number of subjects: 74
Study 37542918 — intervention group
Group type: EXPERIMENTAL
Intervention: Kleijn model
Number of subjects: 74
Study 37542918 — intervention group
Group type: EXPERIMENTAL
Intervention: All models
Number of subjects: 74
Study 37542951 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD females
Number of subjects: 234
Study 37542951 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD males
Number of subjects: 234
Study 37542951 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 234
Study 37543062 — intervention group
Group type: EXPERIMENTAL
Intervention: Flamingo device
Number of subjects: 36
Study 37543062 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic techniques
Number of subjects: 36
Study 37543161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin and methylprednisolone
Number of subjects: 186